The first small Melanotan II pilot is evidence of observed effects under experimental conditions, not evidence that cosmetic use is safe. Its sample size is central to interpretation. Primary report
What was observed
Three male volunteers participated in a single-blind, alternating-day saline-controlled phase 1 study. Increased pigmentation was documented in two participants after treatment. The report also describes nausea, fatigue or somnolence, yawning and stretching, and spontaneous erections. These are systemic observations, not merely changes in skin appearance. Primary report
Our appraisal: do not convert an effect into an endorsement
A visible biological effect and a favorable benefit-harm balance are different propositions. Demonstrating a pigmentation change would not by itself establish long-term skin health, protection against ultraviolet injury, or an acceptable risk profile for unsupervised use.
In a three-person study, an event observed in one individual matters, but it does not provide a stable population frequency. Equally, failure to observe a rare event offers little reassurance. The denominator must remain visible whenever the findings are discussed.
Reading an early-phase report carefully
Our full-paper review would ask how observations were collected, what was prespecified, how masking worked, and how each participant's exposure and follow-up differed. Alternating experimental conditions should not automatically be described as a conventional randomized parallel-group trial.
The paper's historical suggestions for subsequent experimentation are not modern self-administration instructions. This record intentionally does not reproduce an administration schedule. It also does not equate Melanotan II with a different melanocortin compound or with a finished approved medicine.
Frequently asked questions
How many people were studied?
Three male volunteers.
Did every participant have documented pigmentation change?
The abstract reports that finding in two participants.
Were effects limited to pigmentation?
No. The report includes several systemic effects.
Does phase 1 mean proven safe?
No. A development-phase label does not remove uncertainty.
Does pigmentation establish sun protection?
That is a separate outcome and cannot be inferred from color change alone.
Is this a guide for cosmetic self-use?
No. It is an appraisal of a historical experiment, not an endorsement or protocol.
What review remains?
Full methods, individual observations, publication history, and appropriate current safety context before release.